Targeting apoptosis in acute myeloid leukaemia
Autor: | Amine Belhabri, Marie Castets, Philippe A. Cassier, Norbert Vey |
---|---|
Rok vydání: | 2016 |
Předmět: |
0301 basic medicine
Oncology Cancer Research medicine.medical_specialty BCL2 Myeloid Genetic enhancement medicine.medical_treatment Antineoplastic Agents X-Linked Inhibitor of Apoptosis Protein Hematopoietic stem cell transplantation Review Inhibitor of Apoptosis Proteins 03 medical and health sciences 0302 clinical medicine XIAP MDM2 Internal medicine hemic and lymphatic diseases medicine Humans acute myeloid leukaemia Molecular Targeted Therapy business.industry Hematopoietic Stem Cell Transplantation apoptosis Proto-Oncogene Proteins c-mdm2 medicine.disease Transplantation Clinical trial Haematopoiesis Leukemia Leukemia Myeloid Acute Receptors TNF-Related Apoptosis-Inducing Ligand 030104 developmental biology medicine.anatomical_structure Proto-Oncogene Proteins c-bcl-2 030220 oncology & carcinogenesis Stem cell Tumor Suppressor Protein p53 business |
Zdroj: | British Journal of Cancer |
ISSN: | 1532-1827 |
Popis: | Acute myeloid leukaemia (AML) is a molecularly and clinically heterogeneous disease, and its incidence is increasing as the populations in Western countries age. Despite major advances in understanding the genetic landscape of AML and its impact on the biology of the disease, standard therapy has not changed significantly in the last three decades. Allogeneic haematopoietic stem cell transplantation remains the best chance for cure, but can only be offered to a minority of younger fit patients. Molecularly targeted drugs aiming at restoring apoptosis in leukaemic cells have shown encouraging activity in early clinical trials and some of these drugs are currently being evaluated in randomised controlled trials. In this review, we discuss the current development of drugs designed to trigger cell death in AML. |
Databáze: | OpenAIRE |
Externí odkaz: |